Literature DB >> 24941086

Paclitaxel and gemcitabine combinational drug-loaded mucoadhesive delivery system in the treatment of colon cancers.

X-Y Guo1, P Wang1, Q-G Du2, S Han3, S-M Zhu1, Y-F Lv1, G-S Liu1, Z-M Hao4.   

Abstract

The combination of two different types of chemo-therapeutic drugs via nanocarriers is emerged as a promising strategy for treating multiple cancers. Such a co-delivery system will synchronize the drug exposure and synergize the therapeutic effects. Herein, we prepared a paclitaxel (PTX) and gemcitabine (GEM)-loaded N-succinyl chitosan nanoparticles (NSC NP) to target colon cancer. NSC NP showed a pH sensitive swelling at colonic pH and exhibited a sequential release pattern for both the drugs. Binary drug combination exhibited a synergistic cytotoxicity against HT-29 colon cancer cells with a remarkable G2/M phase arrest. Specifically, in vivo antitumor efficacy study showed that NSC NP prolonged the survival time of tumor-bearing mice up to 45 days wherein 50% of mice were still alive. Therefore, these results suggest that co-delivery of drugs with a suitable delivery system could potentially improve the therapeutic efficacy in colon cancers. The study can be further continued by using different types of chemotherapeutic drugs that targets different molecular targets using pH-sensitive nanocarriers. © Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24941086     DOI: 10.1055/s-0034-1375665

Source DB:  PubMed          Journal:  Drug Res (Stuttg)        ISSN: 2194-9379


  6 in total

1.  Synergistic Inhibition of Drug-Resistant Colon Cancer Growth with PI3K/mTOR Dual Inhibitor BEZ235 and Nano-Emulsioned Paclitaxel via Reducing Multidrug Resistance and Promoting Apoptosis.

Authors:  Yali Hu; Kunpeng Zhang; Xingyao Zhu; Xiuyan Zheng; Chao Wang; Xiao Niu; Teng Jiang; Xinhua Ji; Weilin Zhao; Lijuan Pang; Yan Qi; Feng Li; Li Li; Zhiping Xu; Wenyi Gu; Hong Zou
Journal:  Int J Nanomedicine       Date:  2021-03-15

2.  Aerosolized Niosome Formulation Containing Gemcitabine and Cisplatin for Lung Cancer Treatment: Optimization, Characterization and In Vitro Evaluation.

Authors:  Norfatin Izzatie Mohamad Saimi; Norazlinaliza Salim; Noraini Ahmad; Emilia Abdulmalek; Mohd Basyaruddin Abdul Rahman
Journal:  Pharmaceutics       Date:  2021-01-05       Impact factor: 6.321

3.  Data on the in vitro and in vivo anti-tumor effects of itraconazole, paclitaxel, and the two in combination in HT-29 and YM-1 cancer cell line and HT-29 colon cancer xenograft models.

Authors:  Mahdi Ghadi; Seyed Jalal Hosseinimehr; Fereshteh Talebpour Amiri; Alireza Mardanshahi; Zohreh Noaparast
Journal:  Data Brief       Date:  2021-02-11

Review 4.  Current Advances in Chitosan Nanoparticles Based Oral Drug Delivery for Colorectal Cancer Treatment.

Authors:  Hazem Choukaife; Salma Seyam; Batoul Alallam; Abd Almonem Doolaanea; Mulham Alfatama
Journal:  Int J Nanomedicine       Date:  2022-09-07

Review 5.  A technical note on emerging combination approach involved in the onconanotherapeutics.

Authors:  Mohammad Kashif Iqubal; Harsimran Kaur; Shadab Md; Nabil A Alhakamy; Ashif Iqubal; Javed Ali; Sanjula Baboota
Journal:  Drug Deliv       Date:  2022-12       Impact factor: 6.819

6.  Synergistic inhibition of colon cancer cell growth with nanoemulsion-loaded paclitaxel and PI3K/mTOR dual inhibitor BEZ235 through apoptosis.

Authors:  Hong Zou; Li Li; Ines Garcia Carcedo; Zhi Ping Xu; Michael Monteiro; Wenyi Gu
Journal:  Int J Nanomedicine       Date:  2016-05-05
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.